Cargando…

CD7 CAR: sword and shield

Detalles Bibliográficos
Autores principales:	Velasquez, M. Paulina, Mamonkin, Maksim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Blood Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335499/ https://www.ncbi.nlm.nih.gov/pubmed/35900789 http://dx.doi.org/10.1182/blood.2022016595

Ejemplares similares

Defamation lawsuits: academic sword or shield?
por: Hall‐Lipsy, Elizabeth, et al.
Publicado: (2017)

Buckling up against COVID-19 after CAR T-cell therapy
por: Auletta, Jeffery J.
Publicado: (2022)

Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
por: Oh, Bernice Ling Zhi, et al.
Publicado: (2022)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
por: Frigault, Matthew J., et al.
Publicado: (2020)

Another front in COVID-19’s perfect storm
por: Jobe, Shawn M., et al.
Publicado: (2021)

Danger ahead: COVID-19 infections after vaccination
por: Greenberger, Lee M., et al.
Publicado: (2022)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Vaccinations and ITP: keep on track(ing)
por: Bakchoul, Tamam, et al.
Publicado: (2022)

A tale of two alleles: TP53 and transformation in MPNs
por: Brierley, Charlotte, et al.
Publicado: (2022)

Why B(-)other? About the gap of unknowns in ALL
por: Fioretos, Thoas
Publicado: (2022)

Tet2 helps blood cells balance in air
por: Chute, John P.
Publicado: (2022)

CLL and COVID-19: light at the end of the tunnel?
por: Scarfò, Lydia, et al.
Publicado: (2022)

Platelets get particular
por: Rauova, Lubica, et al.
Publicado: (2022)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Vaccination against COVID-19: a challenge in CLL
por: Eichhorst, Barbara
Publicado: (2021)

Understanding VITT(ual) reality
por: Rauova, Lubica, et al.
Publicado: (2021)

Thrombosis with COVID-19: kids get it too
por: Takemoto, Cliff
Publicado: (2021)

VITT(al) insights into vaccine-related clots
por: Strich, Jeffrey R., et al.
Publicado: (2021)

Neutrophils clear sterile inflammatory debris
por: Yost, Christian Con
Publicado: (2021)

This CAR won’t start: predicting nonresponse in ALL
por: Webster, Jonathan A., et al.
Publicado: (2023)

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023)

Prospective validation of the prognostic relevance of CD34(+)CD38(–) AML stem cell frequency in the HOVON-SAKK132 trial
por: Ngai, Lok Lam, et al.
Publicado: (2023)

microRNAs in cancer chemoresistance: The sword and the shield
por: Mondal, Priya, et al.
Publicado: (2021)

On a collision course: SARS-CoV-2 variants and CAR T cells
por: Auletta, Jeffery J.
Publicado: (2023)

FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012)

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
por: Plaks, Vicki, et al.
Publicado: (2021)

Anti-CD37 α-amanitin–conjugated antibodies as potential therapeutic weapons for Richter syndrome
por: Vaisitti, Tiziana, et al.
Publicado: (2022)

Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage
por: Cancelas, Jose A., et al.
Publicado: (2022)

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing
por: Ehrend, Elisabeth, et al.
Publicado: (2021)

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
por: Liebers, Nora, et al.
Publicado: (2022)

MAVS is a double-edged sword
por: Huang, Christina, et al.
Publicado: (2023)

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma
por: Henriquez, Soledad, et al.
Publicado: (2022)

Surrogate test performance for SARS‐CoV‐2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
por: Wendel, Silvano, et al.
Publicado: (2021)

Better a shield than a sword: perspectives on defense and technology
por: Teller, Edward
Publicado: (1987)

Interactions of Viruses with Dendritic Cells: A Double-edged Sword
por: Bhardwaj, Nina
Publicado: (1997)

Antiplatelet therapy: a double-edged sword in head injury?
por: Beynon, Christopher, et al.
Publicado: (2013)

Caveolin-1 in Cardiovascular Disease: A Double-Edged Sword
por: Jia, Guanghong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ivqg5keocv2q1obsfrb8b2n68i